Genmab — April 2017
-
Company Announcement
DARZALEX approved in Europe in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone in patients who have received at least one prior therapy
Genmab to receive milestone payments totaling USD 48 million from Janssen upon the first sale of DARZALEX in the newly approved indications -
milestone!
-
Kanon!!
-
men ingen guidance ændring
-
Det er fascinerende at se hvordan kurven vendte. Fra de -0,7ish til pludselig blå.
Jeg kunne se på aktien at der var sket noget i løbet af de sidste 10ish minutter. Så gik jeg herpå og fik en glædelig nyhed. God fredag til jer andre. -
Nordnet smider og A/N køber.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind